Publications
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
1 February 2021
The COVID-19 pandemic has revealed the broad and devastating health, economic and societal impact of a highly infectious and deadly disease. In addition to the human…
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
1 February 2021
This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates used in transport and the environment exceeded those used in health, which suggests that health may be undervalued by departments of health compared to departments of transport or environment.
2019 OHE Annual Report to the Charity Commission
1 December 2020
We are pleased to submit the third report to the Charity Commission for England and Wales, OHE’s second since becoming a registered charity in December… We…
Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
1 November 2020
By convention, values for generic ‘preference-based’ measures, such as the EQ-5D, are anchored at 1 = full health and 0 = dead. This paper challenges the…
Opportunities to Increase Efficiency in Healthcare
1 October 2020
Substantial economic resources are devoted to healthcare across Europe, but there is evidence that a large proportion of these resources are of limited benefit to patients and society.
How do we Measure the “Value” in Value-Based care?
1 October 2020
Determining and defining value in health care is a persistent challenge in every country. To some extent, what constitutes value depends on perspective, e.g. a pharmaceutical company…
The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
1 September 2020
Vaccines are widely regarded as one of the most important public health achievements of the last century. Health economists, however, have long highlighted the gaps between…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides…
Realising the Broader Value of Vaccines in the UK
8 January 2020
Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided.…